Bronchitis Market Research Report - Forecast to 2027

Bronchitis Market Information: By Type (Acute Bronchitis, Chronic Bronchitis), Diagnosis (Chest X-Ray, Sputum Tests, Pulmonary Function Test), Devices (Drugs, Oxygen Therapy), End-User (Hospitals, Clinics, Pharmacies)- Global Forecast Till 2027

ID: MRFR/Pharma/4303-HCR | February 2021 | Region: Global | 110 pages

Synopsis of the Bronchitis Market


Bronchitis is nothing but the inflammation of the lining of bronchial tubes of the lungs. It is of two types, namely, acute and chronic bronchitis. Acute bronchitis, also known as a chest cold, is found to be very common and develops from a cold or other respiratory infection. On the other hand, chronic bronchitis is a severe condition which is characterized by constant irritation or inflammation of the lining of bronchial tubes. It is included in the Chronic Obstructive Pulmonary Disease (COPD). Shortness of breath, cough, slight fever and chills, production of mucus, fatigue, and chest discomfort are major symptoms of bronchitis. It can be diagnosed through various tests such as chest X-ray, sputum tests, and pulmonary function test.


The bronchitis market is mainly driven by the increasing prevalence of lung diseases such as bronchitis, asthma, COPD, availability of drugs for the treatment, and drugs. Additionally, increasing number of diagnostic services for various chronic diseases and the use of technologically advanced devices for diagnosis also drive the growth of the market. Other factors supporting the market growth are an addiction to smoking and changing lifestyle. However, fierce competition among the existing market players restrains the growth of the market.


The bronchitis market is expected to grow at a CAGR of 5.3% during the forecast period.


Segments  


The bronchitis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the bronchitis market is segmented into acute bronchitis and chronic bronchitis.


On the basis of diagnosis, the bronchitis market is segmented into chest X-ray, sputum tests, and pulmonary function tests.


On the basis of treatment, the bronchitis market is segmented into drugs and oxygen therapy. Drugs is further segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics.


On the basis of end-user, the bronchitis market is segmented into hospitals, clinics, pharmacies, research institutes, and others.


FIGURE 1: Global Bronchitis Market, by Region, 2016 (%)


 Bronchitis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology Bronchitis Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Bronchitis Market                  


The American bronchitis market is segmented into two regions, namely, North America and South America. North America is the largest market with huge patient pool, growing awareness about bronchitis treatment among the people and presence of major players in the market. South America is expected to be the fastest growing market with the increasing demand for diagnostic services.


In Europe, the bronchitis market is driven by the increasing focus on research and development activities for the treatment of chronic bronchitis. Germany and the U.K. occupy a first and second position in the European market which is driven by the increasing demand for diagnostic services for respiratory diseases and the emergence of new players in the market manufacturing various classes of drugs in the market.


The bronchitis market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing environmental population, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases among the adults. Additionally, growth in the number of people addicted to smoking and increasing number of patients with COPD fuel the market in this region.


The Middle Eastern and African market for bronchitis exhibits a steady rise with the growing awareness about causes, diagnosis, and treatment of chronic diseases. The demand for primary care services including diagnostic services for respiratory diseases fuels the market growth in Africa.


Key Players in the Bronchitis Market    


Some of the key players in this bronchitis market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.3% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of lung diseases
  • Availability of drugs for the treatment, and drugs


  • Frequently Asked Questions (FAQ) :


    Bronchitis is an inflammation of the bronchial tubes in the lungs. It can be acute or chronic.

    Bronchitis Market is expected to exhibit a strong 5.3% CAGR over the forecast period till 2027.

    The increasing prevalence of lung diseases is the major driver for the Bronchitis Market.

    The Americas hold the dominant share in the Global Bronchitis Market.

    Leading players in the Bronchitis Market include GSK, Boehringer Ingelheim, and Sanofi, among others.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Bronchitis Market, by Type

    6.1 Introduction

    6.2 Acute Bronchitis

    6.2.1 Market Estimates & Forecast, 2020–2027

    6.3 Chronic Bronchitis

    6.3.1 Market Estimates & Forecast, 2020–2027

    7. Global Bronchitis Market, by Diagnosis

    7.1 Introduction

    7.2 Chest X-ray

    7.2.1 Market Estimates & Forecast, 2020–2027

    7.3 Sputum Test

    7.3.1 Market Estimates & Forecast, 2020–2027

    7.4 Pulmonary Function Test

    7.4.1 Market Estimates & Forecast, 2020–2027

    8. Global Bronchitis Market, by Treatment

    8.1 Introduction

    8.2 Drugs

    8.2.1 Market Estimates & Forecast, 2020–2027

    8.3 Oxygen Therapy

    8.3.1 Market Estimates & Forecast, 2020–2027

    9. Global Bronchitis Market, by End-User

    9.1 Introduction

    9.2 Hospital

    9.2.1 Market Estimates & Forecast, 2020–2027

    9.3 Clinics

    9.3.1 Market Estimates & Forecast, 2020–2027

    9.4 Pharmacies

    9.4.1 Market Estimates & Forecast, 2020–2027

    9.45 Research Institutes

    9.5.1 Market Estimates & Forecast, 2020–2027

    10. Global Bronchitis Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 U.K.

    10.3.1.4 Italy

    10.3.1.5 Spain

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12 Company Profiles

    12.1 GlaxoSmithKline Pharmaceuticals Limited

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Boehringer Ingelheim

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Dr. Reddy’s Laboratories Ltd

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Pfizer Inc.

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Sanofi

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 The Cathay Drug Company Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Kaiser Permanente Inc.

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Diagnostic Tests Industry

    14 Appendix


    LIST OF TABLES

    Table 1 Bronchitis Industry Synopsis, 2020–2027

    Table 2 Global Bronchitis Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Bronchitis Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 5 Global Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 6 Global Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 7 Global Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 8 North America Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 9 North America Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 10 North America Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 11 North America Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 12 US Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 13 US Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 14 US Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 15 US Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 16 Canada Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 17 Canada Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 18 Canada Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 19 Canada Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 20 South America Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 21 South America Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 22 South America Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 23 South America Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 24 Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 25 Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 26 Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 27 Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 28 Western Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 29 Western Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 30 Western Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 31 Western Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 32 Eastern Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 33 Eastern Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 34 Eastern Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 35 Eastern Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 36 Asia Pacific Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 37 Asia Pacific Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 38 Asia Pacific Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 39 Asia Pacific Bronchitis Market, by End-User, 2020–2027, (USD Million)

    Table 40 Middle East & Africa Bronchitis Market, by Type, 2020–2027, (USD Million)

    Table 41 Middle East & Africa Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 42 Middle East & Africa Bronchitis Market, by Treatment, 2020–2027, (USD Million)

    Table 43 Middle East & Africa Bronchitis Market, by End-User, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Bronchitis Market

    Figure 3 Segmentation Market Dynamics for Bronchitis Market

    Figure 4 Global Bronchitis Market Share, by Diagnosis, 2020

    Figure 5 Global Bronchitis Market Share, by Treatment, 2020

    Figure 6 Global Bronchitis Market Share, by End-User, 2020

    Figure 7 Global Bronchitis Market Share, by Region, 2020

    Figure 8 North America Bronchitis Market Share, by Country, 2020

    Figure 9 Europe Bronchitis Market Share, by Country, 2020

    Figure 10 Asia Pacific Bronchitis Market Share, by Country, 2020

    Figure 11 Middle East & Africa Bronchitis Market Share, by Country, 2020

    Figure 12 Global Bronchitis Market: Company Share Analysis, 2020 (%)

    Figure 13 Glaxosmithkline Pharmaceuticals Limited: Key Financials

    Figure 14 Glaxosmithkline Pharmaceuticals Limited: Segmental Revenue

    Figure 16 Glaxosmithkline Pharmaceuticals Limited: Geographical Revenue

    Figure 17 Boehringer Ingelheim: Key Financials

    Figure 18 Boehringer Ingelheim: Segmental Revenue

    Figure 19 Boehringer Ingelheim: Geographical Revenue

    Figure 20 Dr. Reddy’s Laboratories Ltd: Key Financials

    Figure 21 Dr. Reddy’s Laboratories Ltd: Segmental Revenue

    Figure 22 Dr. Reddy’s Laboratories Ltd: Geographical Revenue

    Figure 23 Pfizer Inc.: Key Financials

    Figure 24 Pfizer Inc.: Segmental Revenue

    Figure 25 Pfizer Inc.: Geographical Revenue

    Figure 26 The Cathay Drug Company Inc.: Key Financials

    Figure 27 The Cathay Drug Company Inc.: Segmental Revenue

    Figure 28 The Cathay Drug Company Inc.: Geographical Revenue

    Figure 29 Sanofi: Key Financials

    Figure 30 Sanofi: Segmental Revenue

    Figure 31 Sanofi: Geographical Revenue

    Figure 32 Pfizer Inc: Key Financials

    Figure 33 Pfizer Inc: Segmental Revenue

    Figure 34 Pfizer Inc: Geographical Revenue